Delivery Order SPE2DB22D1041-SPE2DB26FTXX2
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Janumet XR 50-1,000 mg tablets in a quantity of 180 units. This delivery order, valued at approximately $39,906, represents a firm fixed-price contract with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count packages) valued at $3,508.43. This contract utilizes a firm fixed-price structure with an ultimate completion date of September 26, 2025, and was awarded on a competitive basis without any set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count) with a ceiling value of $1,746.19. This firm fixed price delivery order, which is not set-aside and represents a competitively awarded contract, is scheduled for completion by July 25, 2025. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of Janumet XR 50-1,000 mg tablets in a quantity of 180 units. This non-set-aside contract, valued at approximately $35,000, represents a firm fixed-price delivery order with an ultimate completion date of June 5, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) with a ceiling value of $19,423.78. This firm fixed-price delivery order represents a non-set-aside, competitively awarded transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX. The ultimate completion date for this delivery order is August 5,...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Janumet XR 50-1,000 mg tablets (180-count) in the amount of $1,908.41. The contract was awarded on June 16, 2025, with an ultimate completion date of June 17, 2025. This non-competitive delivery order represents a firm fixed-price transaction under AmerisourceBergen's existing Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded a delivery order valued at $1,238.40 to AmerisourceBergen Drug Corp for Janumet XR 50-1,000 mg tablets (180 count) on January 22, 2025, with completion scheduled for January 23, 2025. This firm fixed price delivery order, which carries no set-aside designation, was competitively awarded and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) under a firm fixed-price arrangement. The $9,811.62 delivery order, which represents a non-set-aside competitive award, is scheduled for completion by September 3, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order through its established...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) with a contract ceiling value of $5,550.17. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of September 17, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,528.28 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Janumet XR 50-1,000 mg tablets in a quantity of 180 units. This competitively awarded, non-set-aside contract involves firm fixed pricing and is scheduled for completion by September 2, 2025. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- SPE2DB22D1041Indefinite Delivery Contract
- SPE2DB22D1041-SPE2DB26FTXX2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) valued at $8,599.50. This competitive award, issued without set-aside designation, represents a firm fixed-price delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at approximately $1 billion through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 17, 2025. This delivery order supports the military healthcare supply chain by providing Janumet XR, an antidiabetic medication combining metformin and sitagliptin, to serve Defense Health Agency and other federal medical programs. As a major pharmaceutical distributor, AmerisourceBergen maintains an extensive portfolio of federal contracts with the DLA covering diverse therapeutic areas including diabetes medications, neurological treatments, pain management pharmaceuticals, and specialized medical supplies. The company's demonstrated capability to fulfill competitive federal procurement requirements through its prime indefinite delivery vehicle positions it as a critical vendor for supporting military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 10/16/25 |